Profile data is unavailable for this security.
About the company
Neurotech International Limited is an Australia-based clinical-stage biopharmaceutical development company. The Company is focused predominately on pediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy called NTI164. It has completed a Phase II/III randomized, double-blind, placebo-controlled clinical trial in autism spectrum disorder (ASD) with clinically significant benefits reported across a number of clinically validated measures and safety. In addition, it has completed and reported significant and clinically meaningful Phase I/II trials in ASD and pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS) and pediatric acute-onset neuropsychiatric syndrome (PANS), collectively PANDAS/PANS along with Rett Syndrome. NTI164 is being developed as a therapeutic drug product for a range of neurological disorders in children where neuroinflammation is involved.
- Revenue in AUD (TTM)3.34m
- Net income in AUD-5.07m
- Incorporated2016
- Employees--
- LocationNeurotech International LtdSuite 5 CPC, 145 Stirling HighwayNEDLANDS 6009AustraliaAUS
- Phone+61 89389-3130
- Fax+61 89321-5932
- Websitehttps://neurotechinternational.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Noxopharm Ltd | 2.41m | -3.58m | 32.15m | 1.00k | -- | 5.85 | -- | 13.35 | -0.0123 | -0.0123 | 0.0082 | 0.0188 | 0.2847 | -- | 0.5672 | -- | -42.31 | -43.24 | -48.67 | -52.58 | -- | -- | -148.64 | -170.07 | -- | -- | 0.00 | -- | -60.33 | -9.37 | 76.24 | -- | -- | -- |
| Prescient Therapeutics Ltd | 687.57k | -8.24m | 33.02m | 3.00 | -- | 1.83 | -- | 48.02 | -0.0102 | -0.0102 | 0.0009 | 0.0224 | 0.0284 | -- | 3.31 | -- | -33.97 | -28.85 | -37.31 | -30.66 | -- | -- | -1,198.14 | -2,096.39 | -- | -288.97 | 0.018 | -- | 49.77 | 56.99 | -17.61 | -- | -- | -- |
| Amplia Therapeutics Ltd | 4.44m | -4.50m | 33.32m | 1.00 | -- | 1.63 | -- | 7.51 | -0.0226 | -0.0226 | 0.0222 | 0.0572 | 0.2647 | -- | 2.05 | -- | -26.86 | -25.13 | -32.90 | -27.42 | -- | -- | -101.48 | -206.74 | -- | -- | 0.122 | -- | 286.42 | 144.81 | 27.86 | -- | -6.91 | -- |
| Cynata Therapeutics Ltd | 417.71k | -9.74m | 39.75m | 0.00 | -- | 5.48 | -- | 95.16 | -0.0543 | -0.0543 | 0.0023 | 0.0402 | 0.0305 | -- | 1.85 | -- | -71.18 | -39.49 | -81.37 | -42.96 | -- | -- | -2,332.89 | -515.32 | -- | -- | 0.00 | -- | 18.38 | 16.51 | 31.75 | -- | -- | -- |
| Tryptamine Therapeutics Ltd | -100.00bn | -100.00bn | 44.65m | -- | -- | 8.31 | -- | -- | -- | -- | -- | 0.0049 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0342 | -- | -- | -- | -- | -- | -- | -- |
| IDT Australia Limited | 14.12m | -5.41m | 50.51m | 156.00 | -- | 1.76 | -- | 3.58 | -0.0154 | -0.0154 | 0.0404 | 0.0667 | 0.4734 | 1.84 | 2.62 | -- | -18.15 | -9.77 | -22.59 | -11.61 | 80.11 | 84.61 | -38.33 | -23.12 | 1.12 | -50.05 | 0.1601 | -- | 100.81 | 3.09 | 36.30 | -- | -10.39 | -- |
| Neurotech International Ltd | 3.34m | -5.07m | 54.83m | -- | -- | 4.53 | -- | 16.44 | -0.0054 | -0.0054 | 0.0037 | 0.0117 | 0.3807 | 0.00 | 11.59 | -- | -57.86 | -134.56 | -63.92 | -163.66 | 100.00 | -- | -151.98 | -462.38 | 38.81 | -- | 0.00 | -- | 165.98 | 67.39 | 34.94 | -- | -- | -- |
| Anteotech Ltd | 514.89k | -8.88m | 67.22m | 40.00 | -- | 12.56 | -- | 130.56 | -0.0039 | -0.0039 | 0.0002 | 0.0022 | 0.0699 | -- | 2.55 | -- | -120.47 | -75.24 | -159.35 | -84.74 | -- | -- | -1,724.74 | -1,444.66 | -- | -- | 0.3055 | -- | 26.85 | 27.93 | 29.82 | -- | 68.39 | -- |
| Actinogen Medical Ltd | 291.02k | -13.04m | 70.90m | -- | -- | 3.18 | -- | 243.63 | -0.0061 | -0.0061 | 0.0001 | 0.0072 | 0.0159 | -- | 0.0433 | -- | -71.44 | -48.56 | -78.20 | -51.97 | -- | -- | -4,482.26 | -5,188.44 | -- | -163.10 | 0.0159 | -- | -20.63 | 7.31 | -21.32 | -- | -- | -- |
| Paradigm Biopharmaceuticals Ltd | 6.52m | -58.65m | 78.74m | -- | -- | 3.31 | -- | 12.08 | -0.1875 | -0.1875 | 0.0186 | 0.068 | 0.138 | -- | 1.10 | -- | -124.19 | -52.89 | -150.28 | -58.06 | 99.86 | -- | -899.60 | -543.63 | -- | -961.47 | 0.006 | -- | -23.22 | 14.97 | -12.99 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Merchant Funds Management Pty Ltd.as of 13 Sep 2024 | 50.78m | 4.91% |
